X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company’s lead clinical program, L-130 (psilocin Mucate), a proprietary stabilized conjugate drug candidate, 5-HT2A receptor agonist. It is being evaluating under Phase I clinical trial studies for the treatment of chronic cluster headaches.
Lead Product(s): Psilocin Mucate
Therapeutic Area: Neurology Product Name: L-130
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
L-130 (psilocin analogue), a proprietary stabilized psilocin analogue, which is invetigated for the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs).
Lead Product(s): Psilocin Analogue
Therapeutic Area: Neurology Product Name: L-130
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD, in the United States.
Lead Product(s): DHA
Therapeutic Area: Hematology Product Name: Altemia
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pentec Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
